Session N: Enhancing hepatitis C treatment
Tracks
Track 2
| Thursday, September 12, 2019 |
| 2:00 PM - 3:00 PM |
| Montreal C & D, Level 11 |
Speaker
Dr Joe Doyle
Deputy Program Director, Disease Elimination
Burnet Institute
NURSE-LED, COMMUNITY-BASED HEPATITIS C TREATMENT IS FEASIBLE AND EFFECTIVE AMONG PEOPLE WHO INJECT DRUGS AND THEIR INJECTING NETWORK: THE HCV TREATMENT AND PREVENTION (TAP) STUDY
2:00 PM - 2:15 PMBiography
Dr Doyle is an infectious diseases physician at The Alfred and Monash University Department of Infectious Diseases.
Dr Natasha Martin
Associate Professor
University Of California San Diego
Comparing trial designs for HCV treatment as prevention: An empirical evaluation
2:15 PM - 2:30 PMBiography
Natasha Martin, DPhil is an Associate Professor in the Division of Infectious Diseases and Global Public Health at the University of California San Diego and Honorary Senior Lecturer at the University of Bristol. Dr. Martin is a leading modeler of HCV prevention.among people who inject drugs.
Dr Jake Rance
ECR
UNSW Sydney
PROMISE AND PHARMACEUTICALISATION IN THE ERA OF DIRECT-ACTING ANTIVIRALS
2:30 PM - 2:45 PMBiography
Jake is a Research Fellow with the Centre for Social Research in Health. Before joining the Centre he spent a number of years working in harm reduction services in Sydney’s Kings Cross. Jake has a longstanding interest in the role of qualitative research within the politics of injecting drug use.
Dr. Med. Stefan Christensen
Physician
Centrum für interdisziplinäre Medizin; Infektiologische Gemeinschaftspraxis
REAL-WORLD OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION WITH OPIOID SUBSTITUTION THERAPY, MENTAL DISORDERS, OR ALCOHOL USE DISORDER TREATED WITH GLECAPREVIR/PIBRENTASVIR: DATA FROM THE GERMAN HEPATITIS C-REGISTRY
2:45 PM - 2:50 PMBiography
Stefan Christensen works as an infectious diseases specialist and Medical Director of the Center for Interdisciplinary Medicine (CIM) in Münster, Germany. His research interests include infectious diseases especially in people who inject drugs.
Dr Juliette Foucher
Physician
Hopital de Haut Leveque
Real-world outcomes from people who use drugs with chronic hepatitis C virus infection treated with glecaprevir/pibrentasvir: A pooled analysis of post-marketing observational studies
2:50 PM - 2:55 PMBiography
Juliette Foucher is a hepatologist in Centre Hospitalier Universitaire de Bordeaux, France. She also provides HCV care to people who inject drugs (PWID) in a methadone center, as well as prisoners, in Bordeaux. Dr Foucher also participates in an INSHU program in France to increase HCV treatment by general practitioners.
Dr Sigurdur Olafsson
Director of Hepatology
Landspitali University Hospital
ACTIVELY INJECTING PWID WHO USE STIMULANTS CAN BE SUCCESSFULLY TREATED FOR HCV INFECTION
2:55 PM - 3:00 PMBiography
Sigurdur Olafsson is Associate Professor of Medicine at the University of Iceland Faculty of Medicine and Director of Hepatology in the Division of Gastroenterology, Landspitali – The National University Hospital of Iceland. Dr. Olafsson currently leads a nationwide hepatitis C treatment program in Iceland.
Dr Stephen Barclay
Consultant Hepatologist
NHS Greater Glasgow And Clyde
GLECAPREVIR/PIBRENTASVIR ACHIEVES HIGH SVR RATES AMONGST PEOPLE WHO USE DRUGS: RESULTS FROM A REAL WORLD COHORT.
3:00 PM - 3:05 PMBiography
Dr Stephen Barclay is a Consultant Hepatologist at Glasgow Royal Infirmary in Scotland. He has been heavily involved in scaling up Glasgow’s treatment numbers and shifting HCV care from hospitals, such that the majority is now delivered in prison or community locations, including cirrhosis outreach clinics in addictions settings.
Chair
Brian Conway
Medical Director and President
Vancouver Infectious Diseases Centre
Anne Øvrehus
Clinical Associate Professor
Department of Infectious Diseases, Odense University Hospital
